Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02477020 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 15
- Study locations
NCT02477020: Completed Phase 2 study of Schizophrenia, sponsored by Takeda.
NCT02477020 is a Phase 2 study of Schizophrenia that has completed, run by Takeda. The registered enrollment target is 164 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02477020, a Phase 2 study of Schizophrenia, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
Primary Outcome
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210; higher score indicates greater severity. Least square mean and standard error values were determined using a mixed model for repeated measures (MMRM). A negati
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAK-063 20 mg
Study Locations (15)
California
- - Culver City
- - Lemon Grove
- - Long Beach
- - Pico Rivera
Texas
- - Austin
- - Dallas
- - Houston
Florida
- - Lauderhill
- - Orlando
Alaska
- - Springdale
Georgia
- - Atlanta
Louisiana
- - Lake Charles
Missouri
- - St Louis
Nevada
- - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2016-07-27 |
| Phase | Phase 2 |
What the finished NCT02477020 record still lists
NCT02477020 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02477020 lists 15 locations in 9 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT02477020 about?
NCT02477020 is a clinical study titled "A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia". The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
What is the current status of trial NCT02477020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2015-07-01. Estimated completion is 2016-07-27.
What conditions does trial NCT02477020 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02477020?
The interventions under investigation include: Placebo (DRUG), TAK-063 20 mg (DRUG).
Who is sponsoring clinical trial NCT02477020?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02477020 being conducted?
This trial has 15 study locations across Alaska, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02477020's enrollment target sits among peer trials
164 99th of 315 higher than 215 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI